Cancer Drug Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.

The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.

The global market for Cancer Drug Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Drug Therapy, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cancer Drug Therapy by region & country, by Type, and by Application.

The Cancer Drug Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug Therapy.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Drug Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cancer Drug Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cancer Drug Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Cancer Drug Therapy Product Introduction
    1.2 Global Cancer Drug Therapy Market Size Forecast
        1.2.1 Global Cancer Drug Therapy Sales Value (2019-2030)
        1.2.2 Global Cancer Drug Therapy Sales Volume (2019-2030)
        1.2.3 Global Cancer Drug Therapy Sales Price (2019-2030)
    1.3 Cancer Drug Therapy Market Trends & Drivers
        1.3.1 Cancer Drug Therapy Industry Trends
        1.3.2 Cancer Drug Therapy Market Drivers & Opportunity
        1.3.3 Cancer Drug Therapy Market Challenges
        1.3.4 Cancer Drug Therapy Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Cancer Drug Therapy Players Revenue Ranking (2023)
    2.2 Global Cancer Drug Therapy Revenue by Company (2019-2024)
    2.3 Global Cancer Drug Therapy Players Sales Volume Ranking (2023)
    2.4 Global Cancer Drug Therapy Sales Volume by Company Players (2019-2024)
    2.5 Global Cancer Drug Therapy Average Price by Company (2019-2024)
    2.6 Key Manufacturers Cancer Drug Therapy Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Cancer Drug Therapy Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Cancer Drug Therapy
    2.9 Cancer Drug Therapy Market Competitive Analysis
        2.9.1 Cancer Drug Therapy Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Cancer Drug Therapy Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug Therapy as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Targeted Therapy
        3.1.2 Chemotherapy
        3.1.3 Immunotherapy
    3.2 Global Cancer Drug Therapy Sales Value by Type
        3.2.1 Global Cancer Drug Therapy Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Cancer Drug Therapy Sales Value, by Type (2019-2030)
        3.2.3 Global Cancer Drug Therapy Sales Value, by Type (%) (2019-2030)
    3.3 Global Cancer Drug Therapy Sales Volume by Type
        3.3.1 Global Cancer Drug Therapy Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Cancer Drug Therapy Sales Volume, by Type (2019-2030)
        3.3.3 Global Cancer Drug Therapy Sales Volume, by Type (%) (2019-2030)
    3.4 Global Cancer Drug Therapy Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Angiogenesis Inhibitors
        4.1.2 mTOR Inhibitors
        4.1.3 Monoclonal Antibodies
        4.1.4 Cytokine Immunotherapy (IL-2)
    4.2 Global Cancer Drug Therapy Sales Value by Application
        4.2.1 Global Cancer Drug Therapy Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Cancer Drug Therapy Sales Value, by Application (2019-2030)
        4.2.3 Global Cancer Drug Therapy Sales Value, by Application (%) (2019-2030)
    4.3 Global Cancer Drug Therapy Sales Volume by Application
        4.3.1 Global Cancer Drug Therapy Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Cancer Drug Therapy Sales Volume, by Application (2019-2030)
        4.3.3 Global Cancer Drug Therapy Sales Volume, by Application (%) (2019-2030)
    4.4 Global Cancer Drug Therapy Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Cancer Drug Therapy Sales Value by Region
        5.1.1 Global Cancer Drug Therapy Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Cancer Drug Therapy Sales Value by Region (2019-2024)
        5.1.3 Global Cancer Drug Therapy Sales Value by Region (2025-2030)
        5.1.4 Global Cancer Drug Therapy Sales Value by Region (%), (2019-2030)
    5.2 Global Cancer Drug Therapy Sales Volume by Region
        5.2.1 Global Cancer Drug Therapy Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Cancer Drug Therapy Sales Volume by Region (2019-2024)
        5.2.3 Global Cancer Drug Therapy Sales Volume by Region (2025-2030)
        5.2.4 Global Cancer Drug Therapy Sales Volume by Region (%), (2019-2030)
    5.3 Global Cancer Drug Therapy Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Cancer Drug Therapy Sales Value, 2019-2030
        5.4.2 North America Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Cancer Drug Therapy Sales Value, 2019-2030
        5.5.2 Europe Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Cancer Drug Therapy Sales Value, 2019-2030
        5.6.2 Asia Pacific Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Cancer Drug Therapy Sales Value, 2019-2030
        5.7.2 South America Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Cancer Drug Therapy Sales Value, 2019-2030
        5.8.2 Middle East & Africa Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Cancer Drug Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Cancer Drug Therapy Sales Value
        6.2.1 Key Countries/Regions Cancer Drug Therapy Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Cancer Drug Therapy Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Cancer Drug Therapy Sales Value, 2019-2030
        6.3.2 United States Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Cancer Drug Therapy Sales Value, 2019-2030
        6.4.2 Europe Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Cancer Drug Therapy Sales Value, 2019-2030
        6.5.2 China Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Cancer Drug Therapy Sales Value, 2019-2030
        6.6.2 Japan Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Cancer Drug Therapy Sales Value, 2019-2030
        6.7.2 South Korea Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Cancer Drug Therapy Sales Value, 2019-2030
        6.8.2 Southeast Asia Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Cancer Drug Therapy Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Cancer Drug Therapy Sales Value, 2019-2030
        6.9.2 India Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Cancer Drug Therapy Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Amgen / Allergan
        7.1.1 Amgen / Allergan Company Information
        7.1.2 Amgen / Allergan Introduction and Business Overview
        7.1.3 Amgen / Allergan Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Amgen / Allergan Cancer Drug Therapy Product Offerings
        7.1.5 Amgen / Allergan Recent Development
    7.2 Argos Therapeutics
        7.2.1 Argos Therapeutics Company Information
        7.2.2 Argos Therapeutics Introduction and Business Overview
        7.2.3 Argos Therapeutics Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Argos Therapeutics Cancer Drug Therapy Product Offerings
        7.2.5 Argos Therapeutics Recent Development
    7.3 AstraZeneca
        7.3.1 AstraZeneca Company Information
        7.3.2 AstraZeneca Introduction and Business Overview
        7.3.3 AstraZeneca Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 AstraZeneca Cancer Drug Therapy Product Offerings
        7.3.5 AstraZeneca Recent Development
    7.4 Aveo Pharmaceuticals
        7.4.1 Aveo Pharmaceuticals Company Information
        7.4.2 Aveo Pharmaceuticals Introduction and Business Overview
        7.4.3 Aveo Pharmaceuticals Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Aveo Pharmaceuticals Cancer Drug Therapy Product Offerings
        7.4.5 Aveo Pharmaceuticals Recent Development
    7.5 Bayer
        7.5.1 Bayer Company Information
        7.5.2 Bayer Introduction and Business Overview
        7.5.3 Bayer Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Bayer Cancer Drug Therapy Product Offerings
        7.5.5 Bayer Recent Development
    7.6 Exelixis
        7.6.1 Exelixis Company Information
        7.6.2 Exelixis Introduction and Business Overview
        7.6.3 Exelixis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Exelixis Cancer Drug Therapy Product Offerings
        7.6.5 Exelixis Recent Development
    7.7 Incyte
        7.7.1 Incyte Company Information
        7.7.2 Incyte Introduction and Business Overview
        7.7.3 Incyte Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Incyte Cancer Drug Therapy Product Offerings
        7.7.5 Incyte Recent Development
    7.8 Merck
        7.8.1 Merck Company Information
        7.8.2 Merck Introduction and Business Overview
        7.8.3 Merck Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 Merck Cancer Drug Therapy Product Offerings
        7.8.5 Merck Recent Development
    7.9 Roche
        7.9.1 Roche Company Information
        7.9.2 Roche Introduction and Business Overview
        7.9.3 Roche Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Roche Cancer Drug Therapy Product Offerings
        7.9.5 Roche Recent Development
    7.10 Bristol-Myers Squibb
        7.10.1 Bristol-Myers Squibb Company Information
        7.10.2 Bristol-Myers Squibb Introduction and Business Overview
        7.10.3 Bristol-Myers Squibb Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Bristol-Myers Squibb Cancer Drug Therapy Product Offerings
        7.10.5 Bristol-Myers Squibb Recent Development
    7.11 Eisai
        7.11.1 Eisai Company Information
        7.11.2 Eisai Introduction and Business Overview
        7.11.3 Eisai Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Eisai Cancer Drug Therapy Product Offerings
        7.11.5 Eisai Recent Development
    7.12 Exelixis
        7.12.1 Exelixis Company Information
        7.12.2 Exelixis Introduction and Business Overview
        7.12.3 Exelixis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.12.4 Exelixis Cancer Drug Therapy Product Offerings
        7.12.5 Exelixis Recent Development
    7.13 Genentech (Roche)
        7.13.1 Genentech (Roche) Company Information
        7.13.2 Genentech (Roche) Introduction and Business Overview
        7.13.3 Genentech (Roche) Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.13.4 Genentech (Roche) Cancer Drug Therapy Product Offerings
        7.13.5 Genentech (Roche) Recent Development
    7.14 Novartis
        7.14.1 Novartis Company Information
        7.14.2 Novartis Introduction and Business Overview
        7.14.3 Novartis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.14.4 Novartis Cancer Drug Therapy Product Offerings
        7.14.5 Novartis Recent Development
    7.15 Pfizer
        7.15.1 Pfizer Company Information
        7.15.2 Pfizer Introduction and Business Overview
        7.15.3 Pfizer Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.15.4 Pfizer Cancer Drug Therapy Product Offerings
        7.15.5 Pfizer Recent Development
    7.16 Prometheus Labs
        7.16.1 Prometheus Labs Company Information
        7.16.2 Prometheus Labs Introduction and Business Overview
        7.16.3 Prometheus Labs Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
        7.16.4 Prometheus Labs Cancer Drug Therapy Product Offerings
        7.16.5 Prometheus Labs Recent Development

 8 Industry Chain Analysis
    8.1 Cancer Drug Therapy Industrial Chain
    8.2 Cancer Drug Therapy Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Cancer Drug Therapy Sales Model
        8.5.2 Sales Channel
        8.5.3 Cancer Drug Therapy Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Cancer Drug Therapy Market Trends
    Table 2. Cancer Drug Therapy Market Drivers & Opportunity
    Table 3. Cancer Drug Therapy Market Challenges
    Table 4. Cancer Drug Therapy Market Restraints
    Table 5. Global Cancer Drug Therapy Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Drug Therapy Revenue Market Share by Company (2019-2024)
    Table 7. Global Cancer Drug Therapy Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Cancer Drug Therapy Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Cancer Drug Therapy Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Cancer Drug Therapy Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Cancer Drug Therapy Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Cancer Drug Therapy
    Table 13. Global Cancer Drug Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug Therapy as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Cancer Drug Therapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Cancer Drug Therapy Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Cancer Drug Therapy Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Cancer Drug Therapy Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Cancer Drug Therapy Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Cancer Drug Therapy Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Cancer Drug Therapy Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Cancer Drug Therapy Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Cancer Drug Therapy Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Cancer Drug Therapy Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Cancer Drug Therapy Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Cancer Drug Therapy Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Cancer Drug Therapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Cancer Drug Therapy Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Cancer Drug Therapy Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Cancer Drug Therapy Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Cancer Drug Therapy Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Cancer Drug Therapy Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Cancer Drug Therapy Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Cancer Drug Therapy Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Cancer Drug Therapy Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Cancer Drug Therapy Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Cancer Drug Therapy Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Cancer Drug Therapy Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Cancer Drug Therapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Cancer Drug Therapy Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Cancer Drug Therapy Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Cancer Drug Therapy Sales Value by Region (2019-2024) & (%)
    Table 44. Global Cancer Drug Therapy Sales Value by Region (2025-2030) & (%)
    Table 45. Global Cancer Drug Therapy Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Cancer Drug Therapy Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Cancer Drug Therapy Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Cancer Drug Therapy Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Cancer Drug Therapy Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Cancer Drug Therapy Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Cancer Drug Therapy Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Cancer Drug Therapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Cancer Drug Therapy Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Cancer Drug Therapy Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Cancer Drug Therapy Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Cancer Drug Therapy Sales Volume, (2025-2030) & (K Units)
    Table 57. Amgen / Allergan Company Information
    Table 58. Amgen / Allergan Introduction and Business Overview
    Table 59. Amgen / Allergan Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Amgen / Allergan Cancer Drug Therapy Product Offerings
    Table 61. Amgen / Allergan Recent Development
    Table 62. Argos Therapeutics Company Information
    Table 63. Argos Therapeutics Introduction and Business Overview
    Table 64. Argos Therapeutics Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Argos Therapeutics Cancer Drug Therapy Product Offerings
    Table 66. Argos Therapeutics Recent Development
    Table 67. AstraZeneca Company Information
    Table 68. AstraZeneca Introduction and Business Overview
    Table 69. AstraZeneca Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. AstraZeneca Cancer Drug Therapy Product Offerings
    Table 71. AstraZeneca Recent Development
    Table 72. Aveo Pharmaceuticals Company Information
    Table 73. Aveo Pharmaceuticals Introduction and Business Overview
    Table 74. Aveo Pharmaceuticals Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Aveo Pharmaceuticals Cancer Drug Therapy Product Offerings
    Table 76. Aveo Pharmaceuticals Recent Development
    Table 77. Bayer Company Information
    Table 78. Bayer Introduction and Business Overview
    Table 79. Bayer Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Bayer Cancer Drug Therapy Product Offerings
    Table 81. Bayer Recent Development
    Table 82. Exelixis Company Information
    Table 83. Exelixis Introduction and Business Overview
    Table 84. Exelixis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Exelixis Cancer Drug Therapy Product Offerings
    Table 86. Exelixis Recent Development
    Table 87. Incyte Company Information
    Table 88. Incyte Introduction and Business Overview
    Table 89. Incyte Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Incyte Cancer Drug Therapy Product Offerings
    Table 91. Incyte Recent Development
    Table 92. Merck Company Information
    Table 93. Merck Introduction and Business Overview
    Table 94. Merck Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Merck Cancer Drug Therapy Product Offerings
    Table 96. Merck Recent Development
    Table 97. Roche Company Information
    Table 98. Roche Introduction and Business Overview
    Table 99. Roche Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Roche Cancer Drug Therapy Product Offerings
    Table 101. Roche Recent Development
    Table 102. Bristol-Myers Squibb Company Information
    Table 103. Bristol-Myers Squibb Introduction and Business Overview
    Table 104. Bristol-Myers Squibb Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Bristol-Myers Squibb Cancer Drug Therapy Product Offerings
    Table 106. Bristol-Myers Squibb Recent Development
    Table 107. Eisai Company Information
    Table 108. Eisai Introduction and Business Overview
    Table 109. Eisai Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 110. Eisai Cancer Drug Therapy Product Offerings
    Table 111. Eisai Recent Development
    Table 112. Exelixis Company Information
    Table 113. Exelixis Introduction and Business Overview
    Table 114. Exelixis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 115. Exelixis Cancer Drug Therapy Product Offerings
    Table 116. Exelixis Recent Development
    Table 117. Genentech (Roche) Company Information
    Table 118. Genentech (Roche) Introduction and Business Overview
    Table 119. Genentech (Roche) Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 120. Genentech (Roche) Cancer Drug Therapy Product Offerings
    Table 121. Genentech (Roche) Recent Development
    Table 122. Novartis Company Information
    Table 123. Novartis Introduction and Business Overview
    Table 124. Novartis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 125. Novartis Cancer Drug Therapy Product Offerings
    Table 126. Novartis Recent Development
    Table 127. Pfizer Company Information
    Table 128. Pfizer Introduction and Business Overview
    Table 129. Pfizer Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 130. Pfizer Cancer Drug Therapy Product Offerings
    Table 131. Pfizer Recent Development
    Table 132. Prometheus Labs Company Information
    Table 133. Prometheus Labs Introduction and Business Overview
    Table 134. Prometheus Labs Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 135. Prometheus Labs Cancer Drug Therapy Product Offerings
    Table 136. Prometheus Labs Recent Development
    Table 137. Key Raw Materials Lists
    Table 138. Raw Materials Key Suppliers Lists
    Table 139. Cancer Drug Therapy Downstream Customers
    Table 140. Cancer Drug Therapy Distributors List
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cancer Drug Therapy Product Picture
    Figure 2. Global Cancer Drug Therapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Cancer Drug Therapy Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Cancer Drug Therapy Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Cancer Drug Therapy Report Years Considered
    Figure 7. Global Cancer Drug Therapy Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Cancer Drug Therapy Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Drug Therapy Revenue in 2023
    Figure 10. Cancer Drug Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Targeted Therapy Picture
    Figure 12. Chemotherapy Picture
    Figure 13. Immunotherapy Picture
    Figure 14. Global Cancer Drug Therapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Cancer Drug Therapy Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global Cancer Drug Therapy Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 17. Global Cancer Drug Therapy Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global Cancer Drug Therapy Price by Type (2019-2030) & (USD/Unit)
    Figure 19. Product Picture of Angiogenesis Inhibitors
    Figure 20. Product Picture of mTOR Inhibitors
    Figure 21. Product Picture of Monoclonal Antibodies
    Figure 22. Product Picture of Cytokine Immunotherapy (IL-2)
    Figure 23. Global Cancer Drug Therapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 24. Global Cancer Drug Therapy Sales Value Market Share by Application, 2023 & 2030
    Figure 25. Global Cancer Drug Therapy Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 26. Global Cancer Drug Therapy Sales Volume Market Share by Application, 2023 & 2030
    Figure 27. Global Cancer Drug Therapy Price by Application (2019-2030) & (USD/Unit)
    Figure 28. North America Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 29. North America Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    Figure 30. Europe Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 31. Europe Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    Figure 32. Asia Pacific Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    Figure 34. South America Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 35. South America Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    Figure 36. Middle East & Africa Cancer Drug Therapy Sales Value (2019-2030) & (US$ Million)
    Figure 37. Middle East & Africa Cancer Drug Therapy Sales Value by Country (%), 2023 VS 2030
    Figure 38. Key Countries/Regions Cancer Drug Therapy Sales Value (%), (2019-2030)
    Figure 39. Key Countries/Regions Cancer Drug Therapy Sales Volume (%), (2019-2030)
    Figure 40. United States Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 41. United States Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 42. United States Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 43. Europe Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Europe Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 45. Europe Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 46. China Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 47. China Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 48. China Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 49. Japan Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 50. Japan Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 51. Japan Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 52. South Korea Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 53. South Korea Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 54. South Korea Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 55. Southeast Asia Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 56. Southeast Asia Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 57. Southeast Asia Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 58. India Cancer Drug Therapy Sales Value, (2019-2030) & (US$ Million)
    Figure 59. India Cancer Drug Therapy Sales Value by Type (%), 2023 VS 2030
    Figure 60. India Cancer Drug Therapy Sales Value by Application (%), 2023 VS 2030
    Figure 61. Cancer Drug Therapy Industrial Chain
    Figure 62. Cancer Drug Therapy Manufacturing Cost Structure
    Figure 63. Channels of Distribution (Direct Sales, and Distribution)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.

The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.

The global market for Cancer Drug Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Drug Therapy, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cancer Drug Therapy by region & country, by Type, and by Application.

The Cancer Drug Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug Therapy.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Drug Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cancer Drug Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cancer Drug Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.